Item

中国ワクチンの治験中断…ブラジルで 新型コロナ(2020年11月10日)- Suspension of Chinese vaccine trial ... New coronavirus in Brazil (November 10, 2020)

Title (Dublin Core)

中国ワクチンの治験中断…ブラジルで 新型コロナ(2020年11月10日)- Suspension of Chinese vaccine trial ... New coronavirus in Brazil (November 10, 2020)

Description (Dublin Core)

新型コロナウイルスのワクチン開発をめぐって、ブラジルの衛生当局は9日、「深刻な事態」があったとして中国の製薬会社「シノバック・バイオテック」の治験を中断したと発表しました。 ワクチンは、サンパウロのブタンタン研究所がシノバックと提携し開発していたもので、治験者の1人が死亡したと衛生当局に報告があったということです。 研究所の所長は、死亡と治験との関係はないとしています。 ブラジルでは、少なくとも9,000人が最終段階の治験に参加していました。

Regarding the development of a vaccine for the new coronavirus, Brazilian health officials announced on the 9th that they have suspended clinical trials of Chinese pharmaceutical company Sinovac Biotech because of a "serious situation".
The vaccine was developed by the Butantan Institute in São Paulo in partnership with Sinovac, and one of the participant was reported dead by health officials.
The director of the institute says there is no link between death and clinical trials.
In Brazil, at least 9,000 people participated in final-stage clinical trials.

Video is translated by Youngbin Noh

Date (Dublin Core)

Creator (Dublin Core)

Contributor (Dublin Core)

Event Identifier (Dublin Core)

Partner (Dublin Core)

Type (Dublin Core)

screenshot
video

Link (Bibliographic Ontology)

Publisher (Dublin Core)

Youtube

Controlled Vocabulary (Dublin Core)

English
English
English

Curator's Tags (Omeka Classic)

Contributor's Tags (a true folksonomy) (Friend of a Friend)

Collection (Dublin Core)

English
English

Date Submitted (Dublin Core)

11/10/2020

Date Modified (Dublin Core)

12/09/2020
01/30/21

Date Created (Dublin Core)

11/09/2020

Item sets

This item was submitted on November 10, 2020 by Youngbin Noh using the form “Share Your Story” on the site “A Journal of the Plague Year”: https://covid-19archive.org/s/archive

Click here to view the collected data.

New Tags

I recognize that my tagging suggestions may be rejected by site curators. I agree with terms of use and I accept to free my contribution under the licence CC BY-SA